Hemodynamic, hormonal and electrolyte responses to prenalterol infusion in heart failure.
- 1 March 1983
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 67 (3) , 613-619
- https://doi.org/10.1161/01.cir.67.3.613
Abstract
The hemodynamic, hormonal and electrolyte effects of prenalterol, a synthetic selective beta 1 agonist, were studied in six patients with New York Heart Association functional class II and III heart failure. Prenalterol was infused incrementally at 60, 120 and 240 nmol/min, each rate for 24 hours, producing steady-state plasma prenalterol levels of 52 +/- 3, 121 +/- 6 and 194 +/- 9 nmol/1, respectively (mean +/- SEM). Hemodynamic and hormonal measurements were performed before, during and after prenalterol administration under conditions of constant body posture and a regulated intake of dietary sodium and potassium. Prenalterol induced a statistically significant increase in cardiac index (from 2.6 +/- 0.2 to 3.1 +/- 0.3 1/min/m2), with parallel increases in stroke index (from 28 +/- 2 to 34 +/- 2 ml/beat/m2). Forearm blood flow measurements increased (from 2.9 +/- 0.5 to 4.1 +/- 0.6 ml/min/100 g), while calculated systemic vascular resistance fell, as did pulmonary capillary wedge pressure (from 13.7 +/- 1.6 to 10.5 +/- 1.7 mm Hg). The drug did not alter heart rate, arterial pressure, right heart pressures or the frequency of ventricular premature beats. Prenalterol increased plasma renin activity (from 2.9 +/- 0.8 to 6.6 +/- 1.8 nmol/1/hour), angiotensin II (from 59 +/- 12 to 89 +/- 22 pmol/1), urinary aldosterone excretion (from 41 +/- 10 to 78 +/- 34 nmol/day) and plasma insulin (from 10.6 +/- 2.2 to 19.8 +/- 3.9 mU/1). Circulating catecholamines, cortisol, glucose, glucagon or pancreatic polypeptide did not change. Dose-response studies in five patients showed dose-dependent increments in hemodynamic variables, while hormonal changes plateaued at the second dose level. We conclude that prenalterol infusion augments myocardial contractility, reduces systemic vascular resistance, and stimulates insulin release and the renin-angiotensin-aldosterone system.This publication has 24 references indexed in Scilit:
- Problems in assessment of new pharmacologic agents for the heart failure patientAmerican Heart Journal, 1981
- The actions of insulin on cardiac contractilityLife Sciences, 1981
- Treatment of chronic heart failure with pirbuterol: acute haemodynamic responses.BMJ, 1981
- Hemodynamic effects of inhaled terbutaline in congestive heart failure patients without lung disease: Beneficial cardiotonic and vasodilator beta-agonist properties evaluated by ventricular catheterization and radionuclide angiographyAmerican Heart Journal, 1981
- Hemodynamic effects of intravenous prenalterol in severe heart failureThe American Journal of Cardiology, 1981
- Hemodynamic actions of prenalterol in severe congestive heart failure due to chronic coronary diseaseAmerican Heart Journal, 1981
- A Comparison of Digoxin and Dobutamine in Patients with Acute Infarction and Cardiac FailureNew England Journal of Medicine, 1980
- Free Insulin, C‐Peptide and Glucagon Profiles in Insulin Dependent Diabetes MellitusAustralian and New Zealand Journal of Medicine, 1980
- Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamineLife Sciences, 1977
- Outpatient Screening Tests for Primary AldosteronismAustralian and New Zealand Journal of Medicine, 1976